



## PRESS RELEASE

*For immediate release*

### PERCEPTRONIX TO PRESENT CLINICAL TRIAL RESULTS AT 12<sup>th</sup> WORLD CONFERENCE ON LUNG CANCER

**VANCOUVER, BC, September 2, 07** – Perceptronix Medical Inc. (Perceptronix) announced today they will present results from their clinical trial of LungSign™ at the 12<sup>th</sup> World Conference on Lung Cancer being held in Seoul, Korea September 2-6, 2007. Dr. David Snead, Consultant Pathologist at Walsgrave NHS Trust Hospital Coventry UK, will introduce the data during his oral presentation scheduled for September 2<sup>nd</sup>.

Dr. Snead was an active participant in the clinical trials. Walsgrave NHS Trust Hospital Coventry UK was both a clinical trial site and the first hospital to enter into a commercial agreement with Perceptronix for LungSign™. Between 2003 and 2005, Perceptronix conducted a multi-centered prospective trial to demonstrate the performance of LungSign™. The trial included eight sites in Canada, Europe and Asia, and accrued 986 analyzable specimens (330 lung cancers; 656 negatives) from patients who are at risk for lung cancer. The trial concluded successfully: LungSign™ can identify patients who are at a 2x to 10x elevated risk for lung cancer.

“It is exciting to have this data presented on the world stage,” comments Dr. Roger Kemp, Senior Scientist at Perceptronix. “These trials represent years of in-depth research which ultimately lead to LungSign™ becoming available to physicians. LungSign™ is an important and useful tool in the fight against lung cancer and it is believed that physicians will readily recognize its benefit.” In 2003, Dr. Kemp presented preliminary background data on LungSign™ at the World Lung Conference in Vancouver prior to LungSign™ obtaining approval.

Presented by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer is an excellent opportunity for lung cancer professionals from around the globe to share knowledge, experience and views on lung cancer and probe the many challenging issues surrounding the disease. This year more than 5,000 participants are expected from a wide range of disciplines to share in the forums and presentations on the latest developments in basic and clinical research.

Lung cancer is the most common cause of cancer-related death in men and the second most common in women. Responsible for an estimated [1.3 million deaths](#) worldwide annually, the most significant [risk factor](#) for developing lung cancer is long-term exposure to inhaled [carcinogens](#), especially [tobacco smoke](#). The two main types of lung cancer are small cell lung cancer and non-small cell lung cancer.

#### **About LungSign™**

LungSign™ is based on the ClearSign technology platform developed by Perceptronix. LungSign™ is a safe, simple, non-invasive test used to assess a patient's risk of developing lung cancer. By analyzing the lung cells commonly found in sputum, LungSign™ can detect cancer before it spreads, increasing the likelihood of successful treatment. It has been designed to test for early-stage, pre-symptomatic lung cancer in high-risk individuals — men and women over 50 years old, with a history of cigarette smoking,



exposure to second-hand smoke, or significant exposure to carcinogens such as radon and asbestos. In addition, for patients who have had CT scans that found small, possibly cancerous nodules, LungSign™ results may help shorten the diagnostic process.

#### **About Perceptronix Medical Inc.**

Perceptronix Medical Inc. (founded in 1999) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency, a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

Perceptronix is focused on offering quantitative image cell analysis services for early cancer detection. Perceptronix' products and services offer an improvement over existing detection and localization technologies and provide physicians with increased options for prolonging and improving the quality of patients' lives.

*This news release is not, and under no circumstances, to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.*

- 30 -

#### **Media Contact:**

Amanda Smith, BSc

Smith Biotech

Phone: (778) 846-4116

[amanda@smithbiotech.com](mailto:amanda@smithbiotech.com)